Dongkook Pharmaceutical Co Stock Short Ratio
| 086450 Stock | KRW 16,220 210.00 1.28% |
DongKook Pharmaceutical Co fundamentals help investors to digest information that contributes to DongKook Pharmaceutical's financial success or failures. It also enables traders to predict the movement of DongKook Stock. The fundamental analysis module provides a way to measure DongKook Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DongKook Pharmaceutical stock.
DongKook |
DongKook Pharmaceutical Co Company Short Ratio Analysis
DongKook Pharmaceutical's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, DongKook Pharmaceutical Co has a Short Ratio of 0.0 times. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all Republic of Korea stocks average (which is currently at 0.0).
Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
DongKook Fundamentals
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 1.08 T | |||
| Shares Outstanding | 8.79 M | |||
| Shares Owned By Insiders | 46.60 % | |||
| Shares Owned By Institutions | 17.00 % | |||
| Price To Earning | 19.52 X | |||
| Price To Sales | 0.24 X | |||
| Revenue | 594.19 B | |||
| Gross Profit | 337.12 B | |||
| EBITDA | 83.48 B | |||
| Net Income | 52.92 B | |||
| Cash And Equivalents | 85.44 B | |||
| Total Debt | 13.69 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 2.61 X | |||
| Book Value Per Share | 23,358 X | |||
| Cash Flow From Operations | 44.65 B | |||
| Target Price | 22667.0 | |||
| Number Of Employees | 1.06 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 145.91 B | |||
| Total Asset | 750.08 B | |||
| Retained Earnings | 172.22 B | |||
| Working Capital | 139.53 B | |||
| Current Asset | 203.59 B | |||
| Current Liabilities | 64.06 B | |||
| Z Score | 6.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 750.08 B |
About DongKook Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DongKook Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in DongKook Stock
DongKook Pharmaceutical financial ratios help investors to determine whether DongKook Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DongKook with respect to the benefits of owning DongKook Pharmaceutical security.